Curebus Co., Ltd., a Seoul Bio Hub resident company, announced that CEO Cho Seong-jin received the Magnolia Medal of the Order of Civil Merit at the 2025 Healthcare Technology Promotion Awards hosted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. This award is a government award that recognizes individuals and organizations that have contributed to domestic healthcare technology innovation and industrial development.
CEO Cho Seong-jin was recognized for his contributions to strengthening the competitiveness of the Korean biohealth industry, including the development of new drugs based on small molecule compounds, expanding the global technology export of the domestic new drug pipeline, and fostering an innovation ecosystem based on industry-academia-research cooperation. In particular, the large-scale technology export contract for CV-01 with Italian pharmaceutical company Angelini Pharma, signed in 2024, is said to have received high praise during the review process. CV-01 is progressing smoothly with Phase 1 clinical trials in Korea scheduled to begin in 2024, and its follow-up pipeline, CV-02, has also received IND approval for Phase 1 clinical trials from the US FDA, demonstrating its global development capabilities.
CEO Cho Sung-jin expressed his commitment to accelerating the global development of the pipeline to realize the potential for creating world-class new drugs. Following the signing of a technology transfer agreement worth approximately KRW 500 billion and selection for the 2025 Seoul-Basel Startup Hub Acceleration Program, CureVerse continues its global expansion.
- See more related articles
You must be logged in to post a comment.